Avadel Pharmaceuticals Plc Stock Performance
| AVDL Stock | USD 11.22 0.44 3.77% |
The firm shows a Beta (market volatility) of 1.09, which signifies a somewhat significant risk relative to the market. Avadel Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Avadel Pharmaceuticals is expected to follow. At this point, Avadel Pharmaceuticals has a negative expected return of -0.35%. Please make sure to confirm Avadel Pharmaceuticals' standard deviation, kurtosis, relative strength index, as well as the relationship between the maximum drawdown and day median price , to decide if Avadel Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Avadel Pharmaceuticals PLC has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's fundamental indicators remain quite persistent which may send shares a bit higher in December 2024. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
Actual Historical Performance (%)
One Day Return (1.72) | Five Day Return 7 | Year To Date Return (19.75) | Ten Year Return (18.72) | All Time Return (2.47) |
1 | Avadel Pharmaceuticals Stock Price Down 4.9 | 09/13/2024 |
2 | Renaissance Technologies LLC Has 905,000 Holdings in Avadel Pharmaceuticals plc - MarketBeat | 10/08/2024 |
3 | Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ Extended-Release Oral Suspension for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patie... | 10/17/2024 |
4 | Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation | 10/31/2024 |
5 | Avadel Pharmaceuticals PLC Q3 2024 Everything You Need To Know Ahead Of Earnings | 11/11/2024 |
6 | Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2024 Financial Results | 11/12/2024 |
7 | Avadel Pharmaceuticals plc Q3 2024 Earnings Call Transcript | 11/13/2024 |
8 | Avadel Pharmaceuticals Third Quarter 2024 Earnings Beats Expectations | 11/14/2024 |
9 | Avadel Pharmaceuticals PLC Shares Up 3 percent on Nov 22 | 11/22/2024 |
| Begin Period Cash Flow | 74 M |
Avadel |
Avadel Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,486 in Avadel Pharmaceuticals PLC on August 28, 2024 and sell it today you would lose (364.00) from holding Avadel Pharmaceuticals PLC or give up 24.5% of portfolio value over 90 days. Avadel Pharmaceuticals PLC is currently does not generate positive expected returns and assumes 4.3455% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than Avadel, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Avadel Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Avadel Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Avadel Pharmaceuticals PLC, and traders can use it to determine the average amount a Avadel Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0809
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AVDL |
Estimated Market Risk
| 4.35 actual daily | 38 62% of assets are more volatile |
Expected Return
| -0.35 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Avadel Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Avadel Pharmaceuticals by adding Avadel Pharmaceuticals to a well-diversified portfolio.
Avadel Pharmaceuticals Fundamentals Growth
Avadel Stock prices reflect investors' perceptions of the future prospects and financial health of Avadel Pharmaceuticals, and Avadel Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Avadel Stock performance.
| Return On Equity | -1.0 | ||||
| Return On Asset | -0.34 | ||||
| Profit Margin | (1.12) % | ||||
| Operating Margin | (0.31) % | ||||
| Current Valuation | 1.06 B | ||||
| Shares Outstanding | 96.27 M | ||||
| Price To Earning | 61.46 X | ||||
| Price To Book | 15.05 X | ||||
| Price To Sales | 8.13 X | ||||
| Revenue | 27.96 M | ||||
| Gross Profit | 16.59 M | ||||
| EBITDA | (149.12 M) | ||||
| Net Income | (160.28 M) | ||||
| Cash And Equivalents | 104.12 M | ||||
| Cash Per Share | 1.74 X | ||||
| Total Debt | 35.38 M | ||||
| Debt To Equity | 2.63 % | ||||
| Current Ratio | 2.72 X | ||||
| Book Value Per Share | 0.98 X | ||||
| Cash Flow From Operations | (128.51 M) | ||||
| Earnings Per Share | (1.09) X | ||||
| Market Capitalization | 1.27 B | ||||
| Total Asset | 164.7 M | ||||
| Retained Earnings | (745.5 M) | ||||
| Working Capital | 97.35 M | ||||
| Current Asset | 177.85 M | ||||
| Current Liabilities | 59.19 M | ||||
About Avadel Pharmaceuticals Performance
By examining Avadel Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Avadel Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Avadel Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 4 K | 4.2 K | |
| Return On Tangible Assets | (1.08) | (1.03) | |
| Return On Capital Employed | (1.08) | (1.02) | |
| Return On Assets | (0.97) | (0.92) | |
| Return On Equity | (1.83) | (1.92) |
Things to note about Avadel Pharmaceuticals performance evaluation
Checking the ongoing alerts about Avadel Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Avadel Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Avadel Pharmaceuticals generated a negative expected return over the last 90 days | |
| Avadel Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 27.96 M. Net Loss for the year was (160.28 M) with profit before overhead, payroll, taxes, and interest of 16.59 M. | |
| Avadel Pharmaceuticals PLC currently holds about 104.12 M in cash with (128.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.74. | |
| Avadel Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 80.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Avadel Pharmaceuticals PLC Shares Up 3 percent on Nov 22 |
- Analyzing Avadel Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Avadel Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Avadel Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Avadel Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Avadel Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Avadel Pharmaceuticals' stock. These opinions can provide insight into Avadel Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avadel Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avadel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.09) | Revenue Per Share 1.036 | Quarterly Revenue Growth 26.743 | Return On Assets (0.34) | Return On Equity (1.00) |
The market value of Avadel Pharmaceuticals is measured differently than its book value, which is the value of Avadel that is recorded on the company's balance sheet. Investors also form their own opinion of Avadel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Avadel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avadel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Avadel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avadel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avadel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avadel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.